Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.
News|Articles|August 27, 2026
Daraxonrasib Approved: What Oncology Nurses Must Know About Rasonque
Author(s)Alex Biese
Fact checked by: Alex Biese
The FDA has approved daraxonrasib for metastatic pancreatic cancer. MSK's Mary Larsen, MSN, RN, OCN, shares essential nursing protocols for care.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) has approved daraxonrasib (Rasonque; Revolution Medicines, Inc.) once-daily oral tablets. This first-in-class, broad-spectrum RAS(ON) multi-selective inhibitor is the first targeted therapy approved to directly inhibit RAS proteins—the key growth driver in more than 90% of pancreatic ductal adenocarcinoma (PDAC) cases.
Related to this article
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.
An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology nursing takeaways.
FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.
FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
Marieta Branis, APN, discusses individualized breast cancer care, monitoring for ADC and oral therapy toxicities, younger patients, and survivorship.
Advertisement
Advertisement